IMOCUR stimulates production of immunoglobulins; preliminary results concerning a correlation between in vitro and in vivo experiments.

The bacterial extract IMOCUR is described as an in vivo stimulant of antibody production during animal testing and human clinical trials. Using a slightly modified procedure (13) dealing with in vitro immunoglobulin production by C57B1/6 mouse spleen cells, we have shown that IMOCUR potentiates spontaneous IgM production. In order to explore the putative relation between this in vitro activity and the current in vivo control test (stimulation of plaque-forming cell production after sheep red blood cell injection to Balb/c mouse), we have assayed 10 lyophilisates in vitro and in vivo before and after heat inactivation (80 degrees C, 7 days in a saturated water atmosphere). Results have shown that this treatment inhibits, respectively, totally and partially in vivo and in vitro activities. Thus the in vitro technique seems to be appropriate for the control of activity of the various batches of IMOCUR. Experiments are under way to clarify the mathematical correlation which may exist between the in vitro and in vivo experiments.